FEATURES OF ARTERIAL HYPERTENSION IN PATIENTS WITH COMORBIDITY

Distinctive feature of hypertension is the high frequency of a komorbidnost. Patients with hypertension, as a rule, have one or several accompanying pathologies, treat the most often meeting: chronic obstructive pulmonary disease, cerebrovascular disease, diabetes mellitus, hypothyroidism and others. The komorbidnost leads to mutual influence on the course of diseases, character and gravity of complications, quite often complicates diagnostics, defines features of the choice of anti-hypertensive drugs. In references of the European society of cardiologists and the European society on hypertension, the American association of heart and the American Association of strokes, the Russian cardiologic society and the Russian medical society on an arterial hypertonia the approaches to tactics of maintaining patients with hypertension and the accompanying pathology based on data of evidential medicine are designated. Existence of a komorbidnost at patients with hypertension defines not only the choice of antihypertensive drugs, but also target values of arterial pressure. Recently the available representations are added with results of new researches and meta-analyses. Patients with hypertension and a komorbidnost demand individual approach, complex diagnostics and treatment taking into account all available pathologies.

1. Almagro P, Cabrera FJ, Diez J, Boixeda R, Alonso Ortiz MB, Murio C et al. Comorbidities and short- term prognosis in patients hospitalized for acute exacerbation of COPD. The ESMI study. Chest. 2012;142(5):1126–1133. doi: 10.1378/chest.11-2413

2. Park HJ, Leem AY, Lee SH, Song JH, Park MS, Kim YS et al. Comorbidities in obstructive lung disease in Korea: data from the fourth and fifth Korean National Health and Nutrition Examination Survey. Int. J. Chron. Obstruct. Pulmon. Dis. 2015;10:1571–1582. doi: 10.2147/COPD.S85767

3. Hillas G, Perlikos F, Tsiligianni I, Tzanakis N. Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:95–109. doi: 10.2147/COPD.S54473

4. Camiciottoli G, Bigazzi F, Magni C, Bonti V, Diciotti S, Bartolucci M et al. Prevalence of comorbidities according to predominant phenotype and severity of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2016;11:2229–2236. doi: 10.2147/COPD.S111724

5. Rabahi MF, Pereira SA, Silva Júnior JL, de Rezende AP, Castro da Costa A, de Sousa Corrêa K et al. Prevalence of chronic obstructive pulmonary disease among patients with systemic arterial hypertension without respiratory symptoms. Int J Chron Obstruct Pulmon Dis. 2015;10(1):1525-9. doi: 10.2147/COPD.S85588

6. Haeusler KG, Herm J, Konieczny M, Grittner U, Lainscak M, Endres M et al. Impact of chronic inflmmatory airway disease on stroke severity and long-term survival after ischemic stroke – a retrospective analysis. BMC Neurol. 2015;15:164. doi: 10.1186/s12883-015-0414-1

7. Portegies ML, Lahousse L, Joos GF, Hofman A, Koudstaal PJ, Stricker BH et al. Chronic obstructive pulmonary disease and the risk of stroke: the Rotterdam study. Am. J. Respir. Crit. Care Med. 2015;193(3):251-8. doi: 10.1164/rccm.201505-0962OC

8. Kryuchkova ON, Turna EY, Martynyuk MA. Arterial hypertension in patients with chronic obstructive pulmonary disease: pathogenetic features and daily dynamics of blood. Crimean Journal of Internal Diseases. 2015;2:5-9. (in Russ).

9. Karoli NA, Dolishnyaya GR, Rebrov AP. 24-hour arterial stiffness values in men with different phenotypes of chronic obstructive pulmonary disease concurrent with hypertension. The Clinician. 2015;9(1):37-41. (In Russ.) doi: 10.17650/1818-8338-2015-1-37-41

10. Gurevich MA, Dolgova EV, Kuzmenko NA. Chronic obstructive pulmonary disease, arterial hypertension and coronary artery disease: features of pathogenesis, clinical picture and management. RMJ. 2016;16:1098–1102. (in Russ)

11. Chazova IE, Chuchalin AG, Zykov KA, Ratova LG. the diagnosis and treatment of patients with arterial hypertension and chronic obstructive inflammatory pulmonary diseases (guidelines of The Russian Medical Society On Arterial Hypertension and The Russian Respiratory Society). SYSTEMIC HYPERTENSION. 2013;10(1):5-34. (In Russ.)

12. Grigorieva NY. The comorbid patient with AG and HOBL. Attending physician. 2016;7:24-27. (in Russ).

13. Mortensen EM, Copeland LA, Pugh MJ, Restrepo MI, de Molina RM, Nakashima B et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10:45. doi: 10.1186/1465-9921-10-45

14. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–59. doi: 10.1056/NEJMoa0801317

15. Podowski M, Calvi C, Metzger S, Misono K, Poonyagariyagorn H, Lopez-Mercado A et al. Angiotensin receptor blockade attenuates cigarette smoke–induced lung injury and rescues lung architecture in mice. J Clin Invest. 2012;122(1):229–40. doi: 10.1172/JCI46215

16. Chandratilleke MG, Carson KV, Picot J, Brinn MP, Esterman AJ, Smith BJ. Physical training for asthma. Cochrane Database Syst Rev. 2012;(5):CD001116. doi: 10.1002/14651858.CD001116.pub3

17. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29-322. doi: 10.1161/CIR.0000000000000152

18. Fonyakin AV, Geraskina LA. Arterial Hypertension and Optimization of Medication Prevention of Ischemic Stroke. Cardiology. 2016;(2):73-78. (in Russ.). doi: 10.18565/cardio.2016.2.73-78

19. Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S et al. Guidelines for the Primary Prevention of Stroke. A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014;45(12):3754-3832. doi: 10.1161/STR.0000000000000046

20. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. European Heart Journal. 2013;34(28):2159–2219. doi: 10.1093/eurheartj/eht151

21. Parsons C, Murad MH, Andersen S, Mookadam F, Labonte H. The effect of antihypertensive treatment on the incidence of stroke and cognitive decline in the elderly: a meta-analysis. Future Cardiol. 2016;12(2):237-48. doi: 10.2217/fca.15.90

22. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and metaanalyses of randomized trials. J Hypertens. 2016;34(4):613-22. doi: 10.1097/HJH.0000000000000881

23. Akioyamen L, Levine M, Sherifali D, O’Reilly D, Frankfurter C, Pullenayegum E et al. Cardiovascular and cerebrovascular outcomes of long-term angiotensin receptor blockade: metaanalyses of trials in essential hypertension. J Am Soc Hypertens. 2016;10(1):55-69. doi: 10.1016/j.jash.2015.11.005

24. Korostovtseva LS, Zvartau NE, Barantsevich ER, Konradi AO. The choice of the antihypertensive drug in special conditions: evidence-based data in co-morbid neurology diseases (part 5). “Arterial’naya Gipertenziya” (“Arterial Hypertension”). 2015;21(2):116-120. (In Russ.) doi: 10.18705/1607-419X-2015-21-2-116-120

25. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD et al. Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack. A Guideline for Healthcare Professionals From the American Heart Association/ American Stroke Association. Stroke. 2014;45(7):2160-2236. doi: 10.1161/STR.0000000000000024

26. Liu S, Li C, Li T, Xiong J, Zhao X. Effects of Early Hypertension Control after Ischaemic Stroke on the Outcome: A Meta-Analysis. Cerebrovasc Dis. 2015;40(5-6):270-8. doi: 10.1159/000441097

27. Katsanos AH, Filippatou A, Manios E, Deftereos S, Parissis J, Frogoudaki A et al. Blood Pressure Reduction and Secondary Stroke Prevention: A Systematic Review and Metaregression Analysis of Randomized Clinical Trials. Hypertension. 2017;69(1):171-179. doi: 10.1161/HYPERTENSIONAHA.116.08485

28. Xue H, Lu Z, Tang WL, Pang LW, Wang GM, Wong GW et al. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev. 2015 Jan 11;1:CD008170. doi: 10.1002/14651858.CD008170.pub2

29. Wang WT, You LK, Chiang CE, Sung SH, Chuang SY, Cheng HM et al. Comparative Effectiveness of Blood Pressure-lowering Drugs in Patients who have Already Suffered From Stroke: Traditional and Bayesian Network Meta-analysis of Randomized Trials. Medicine (Baltimore). 2016;95(15): 3302. doi: 10.1097/MD.0000000000003302

30. Jeffers BW, Robbins J, Bhambri R. Efficacy of Calcium Channel Blockers Versus Other Classes of Antihypertensive Medication in the Treatment of Hypertensive Patients With Previous Stroke and/or Coronary Artery Disease: A Systematic Review and Meta-Analysis. Am J Ther. 2017;24(1):e68-e80. doi: 10.1097/MJT.0000000000000369

31. Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM. Associations of anti-hypertensive treatments with Alzheimer’s disease, vascular dementia and other dementias. J Alzheimers Dis. 2011;26(4):699- 708. doi: 10.3233/JAD-2011-110347

32. Tully PJ, Hanon O, Cosh S, Tzourio C. Diuretic antihypertensive drugs and incident dementia risk: a systematic review, metaanalysis and meta-regression of prospective studies. J Hypertens. 2016;34(6):1027-35. doi: 10.1097/HJH.0000000000000868

33. Dzhanashiya PH, Selivanova GB. The ages differences in blood pressure dynamics, renin-aldosteron system state and lipid profile in patients with arterial hypertension and thyreotoxycosis. Russian cardiological journal. 2003;(6):16-18. (in Russ).

34. Skibitsky VV, Pykhalova NE, Fendrikova AV. Combined arterial hypertension therapy in women with metabolic syndrome and hypothyroidism. Kuban scientific medical vestnik. 2011;(6):149- 154. (in Russ).

35. Chesnikova AI, Skarzhinskaya NS, Safronenko VA. Features of a current of an arterial hypertensia at patients with a primary hypothyroidism. Kuban scientific medical vestnik. 2012;(1):192- 196. (in Russ).

36. Petunina NA. Cardiovascular system at diseases of a thyroid gland. Heart. 2003;2-6(12):272-279. (in Russ).

37. Petunina NA. Features of therapy of diseases of a thyroid gland at patients with cardialy pathology. Russian medical journal. 2005;13(28):1927-1932. (in Russ).

38. Fadeev VV, Melnichenko GA, Dedov II. Diseases of a thyroid gland in schemes. M.: GEOTAR – Media; 2006. (in Russ).

39. Selivanova GB. New prospects of a clinical use of antagonists of a calcium: arterial hypertension at patients with a hypothyrosis. Consilium medicum. 2006;8(11):109-113. (in Russ).

40. Skarzhinskaya NS, Chesnikova AI, Safronenko VA. Evaluating the effectiveness of various schemes of antihypertensive therapy in patients with hypertension and primary hypothyroidism in the stage of medical compensation. Kuban scientific medical vestnik. 2011;(6):130-138. (in Russ).

41.